Taigen Biopharmaceuticals Holdings Ltd (4157) — Long-term Investment Intensity
Taigen Biopharmaceuticals Holdings Ltd (4157) has a Long-term Investment Intensity of 14.1% as of December 2019. Long-term investments of NT$133.82 Million represent 14.1% of total assets of NT$946.11 Million. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. Check Taigen Biopharmaceuticals Holdings Ltd investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
LT Investment Intensity
Long-term Investments
Total Assets
Country
Taigen Biopharmaceuticals Holdings Ltd Long-term Investment Intensity (2017–2019)
This chart shows how Taigen Biopharmaceuticals Holdings Ltd's Long-term Investment Intensity has evolved across 3 annual periods from 2017 to 2019. As of December 2019, the intensity stands at 14.1%, reflecting long-term investments of NT$133.82 Million against total assets of NT$946.11 Million TWD. Explore 4157 operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
Annual Long-term Investment Intensity for Taigen Biopharmaceuticals Holdings Ltd (2017–2019)
The table below presents the year-by-year Long-term Investment Intensity for Taigen Biopharmaceuticals Holdings Ltd from 2017 to 2019, covering 3 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. For market capitalisation and broader financial context, see 4157 market cap.
| Year | LT Investment Intensity | LT Investments (TWD) | Total Assets | Change (pp) |
|---|---|---|---|---|
| 2019 | 14.1% | NT$133.82 Million | NT$946.11 Million | ▼ -9.4 pp |
| 2018 | 23.6% | NT$280.07 Million | NT$1.19 Billion | ▼ -1.2 pp |
| 2017 | 24.8% | NT$376.91 Million | NT$1.52 Billion | — |